**Supplementary Table S7** Diagnostic performance of HPV vs. HPV + *ZNF582* for abnormal (LSIL/HSIL) cytology

| Parameters | Biomarkers | |
| --- | --- | --- |
| | HPV | HPV + *ZNF582* |
| Disease (cytological)[a] | | |
| Present (LSIL/HSIL) | 125 (80) | 125 (80) |
| Absent (NILM) | 31 (20) | 31 (20) |
| Total | 156 (100) | 156 (100) |
| Diagnostic performance[b, c] | | |
| Sensitivity | 112/125 (90) | 125/125 (100) |
| Specificity | 25/31 (81) | 21/31 (68) |
| PPV | 112/118 (95) | 125/135 (93) |
| NPV | 25/38 (66) | 21/21 (100) |
| False positive | 6/118 (5) | 10/135 (7) |
| False negative | 13/38 (34) | 0/21 (0) |
| LR + test (TP/FP) | 4.74 | 3.13 |
| LR - test (FN/TN) | 0.123 | 0 |
| Accuracy, % | 137/156 (88) | 146/156 (94) |

FN, false negative; FP, false positive; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; LR, likelihood ratio; LSIL, low-grade squamous intraepithelial lesion; NILM, negative for intraepithelial lesion/malignancy; TN, true negative; TP, true positive; ZNF, *ZNF582* gene.

[a]The disease state was defined by the cytological diagnosis of the specimen at study entry. It served as the reference standard for the clinical performance of the molecular tests, i.e., HPV and HPV + *ZNF582*.

[b]The positive outcome or "classification threshold" probabilities used for classification of outcomes for HPV and HPV + *ZNF582* were 0.53 and 0.33, respectively.

[c]Values are n/N (%) unless denoted otherwise.